| Drug Name: | Tirofiban (144494-65-5) |
|---|---|
| PubChem ID: | 60947 |
| SMILES: | CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O |
| InchiKey: | COKMIXFXJJXBQG-NRFANRHFSA-N |
| Therapeutic Category: | Cardiovascular Agents, Fibrin Modulating Agents, Fibrinolytic Agents, Hematologic Agents, Platelet Aggregation Inhibitors |
| Molecular Weight (dalton) | : | 440.606 |
| LogP | : | 2.9505 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 3 |
| Total Polar Surface Area | : | 104.73 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Antiplatelet Effect | Integrin Alpha-IIb precursor (P08514) | Antiplatelet effect [ ADR Type 1 ] | Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. |
| Antiplatelet Effect | Integrin beta-3 precursor (P05106) | Antiplatelet effect [ ADR Type 1 ] | Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category